News | September 21, 2008

3D Conformal RT Shortens Treatment Time, Study Says

September 22, 2008 - Women with early stage breast cancer who choose lumpectomy and radiation as their treatment option may be able to significantly shorten their total treatment time using three-dimensional conformal radiation therapy (3DCRT) according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG, an NCI-funded national clinical trials group, is a clinical research component of the American College of Radiology (ACR).

Breast conserving therapy of lumpectomy followed by radiotherapy, with its superior cosmetic result and equivalent survival outcome, is an accepted option instead of mastectomy for many patients with stage I or II breast cancer. A major drawback of standard breast conserving therapy is that it is a more complicated treatment regimen requiring five to seven weeks to complete radiotherapy. Using 3DCRT to more accurately target the radiation and spare uninvolved areas of the breast, RTOG researchers are able to deliver radiation to the tumor bed site in higher doses more quickly thus shortening the post lumpectomy treatment time to one week.

“These are very preliminary but encouraging results for women who need treatment but who also have families, careers and other factors to consider when deciding on breast conservation therapy for cancer," said Frank Vicini, M.D., chief of oncology, Beaumont Hospitals, Royal Oak, Mich. “We are leading a large, National Cancer Institute-sponsored clinical trial to give us more information on the benefits vs. risks of accelerated breast irradiation in one week compared to standard radiation therapy for up to seven weeks.”

The phase II study, RTOG 0319, enrolled 58 women from 24 academic and community institutions in the U.S. and Canada from August 2003 until April 2004. The women enrolled on the study received 3DCRT twice daily, with each dose separated by six hours, for five consecutive days. Fifty-three of the patients were evaluable for efficacy reporting with a median follow-up of 4.0 years. At four years the disease-free survival rate was 84 percent, mastectomy-free survival was 90 percent, and overall survival was 96 percent. This is comparable to published rates for standard therapy.

“RTOG is able to test innovative treatment options such as accelerated partial breast irradiation with 3DCRT in a wide variety of treatment facilities both in the community and in academic centers. This allows us to respond to the needs of community physicians and moves proven, new therapies into general practice faster,” said Walter J. Curran, Jr., the RTOG Group Chair, and the Lawrence W. Davis Professor and chair of the department of radiation oncology in the Emory School of Medicine and chief medical officer of the Emory Winship Cancer Institute.

For more information: www.rtog.org, www.acr.org

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...